Trial reportDiabetes, obesity & metabolism2005
Effects of metformin on the body composition in subjects with risk factors for type 2 diabetes.
Trial report in Diabetes, obesity & metabolism, 2005. The graph read 2 numbers from its abstract, feeding 1 cell of the map: it . Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
In the metformin group, there was a decrease in fat weight from 25.9 +/- 9.4 to 20.8 +/- 9.2 kg, p < 0.01, an increase in lean weight from 57.05 +/- 13.6 to 61.9 +/- 16.5 kg, p < 0.01, an increase in basal metabolism from 1735 +/- 413 to 1878 +/- 505 calories/day, p < 0.05 and an increase in body water, p < 0.05.
In the metformin group, there was a decrease in fat weight from 25.9 +/- 9.4 to 20.8 +/- 9.2 kg, p < 0.01, an increase in lean weight from 57.05 +/- 13.6 to 61.9 +/- 16.5 kg, p < 0.01, an increase in basal metabolism from 1735 +/- 413 to 1878 +/- 505 calories/day, p < 0.05 and an increase in body water, p < 0.05.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Metformin×body weight & composition
No readable resultOpen on the map →What to test next →19 readable studies in this cell: 7 favour the treatment, 6 find no difference, 6 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Prevalence and risk factors of sarcopenia in Asian adults with type 2 diabetes: A systematic review and meta-analysis.Journal of diabetes investigation · 2026Pooled it
- Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2019 · on this mapPooled it
- Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis.European journal of clinical pharmacology · 2019Pooled it
- Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.The Journal of clinical endocrinology and metabolism · 2014Trial
- Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Risk Factors for Sarcopenia in Women with Type 2 Diabetes and the Effects of Metformin: A Cross-Sectional Study of 7,731 Patients from the UK Biobank.International journal of women's health · 2025Article
- Sex differences in the skeletal muscle response to metformin treatment and the possible association with gut-muscle axis in rats.Frontiers in endocrinology · 2025Article
- Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia.Cells · 2023Review
- Overweight and Obese Adult Patients Show Larger Benefits from Concurrent Training Compared with Pharmacological Metformin Treatment on Insulin Resistance and Fat Oxidation.International journal of environmental research and public health · 2022Article
- Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications.Journal of cachexia, sarcopenia and muscle · 2021Review
- Metformin Treatment in Old Rats and Effects on Mitochondrial Integrity.Rejuvenation research · 2021Article
- Effects of anti-diabetic drugs on sarcopenia: Best treatment options for elderly patients with type 2 diabetes mellitus and sarcopenia.World journal of clinical cases · 2021Review
- Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin.Journal of diabetes research · 2020 · on this mapObservational
- Body composition changes in diabetes and aging.Journal of diabetes and its complications · 2019Review
- AMPK activation--protean potential for boosting healthspan.Age (Dordrecht, Netherlands) · 2014Review
- Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin.Journal of diabetes and metabolic disorders · 2014Article
- The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus.Current therapeutic research, clinical and experimental · 2013Article
- Effect of combined treatment with clozapine and metformin on fasting blood glucose, insulin level, and expression of the glucose transporter-2 (GLUT2) in Sprague-Dawley rats.Shanghai archives of psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
objectivesTo measure the effect of metformin on the body composition, insulin resistance and sensitivity in subjects with risk factors for type 2 diabetes mellitus (type 2 DM).
designPlacebo-controlled clinical trial. MATERIAL AND
methodsTwenty-three subjects with risk factors for type 2 DM were randomly assigned to receive 850 mg of metformin or a placebo twice a day for 2 months. Before and after the treatment, the body mass index and waist/hip ratio were calculated, the body composition was measured through bioelectric impedance and the fasting levels of blood glucose, insulin, triglycerides and cholesterol were measured. The level of insulin resistance was calculated by the homeostatic model and the level of sensitivity by the quantitative insulin sensitivity check index method. The Wilcoxon rank test was used.
resultsTwenty-one subjects completed the study, 12 of the metformin group and nine of the placebo group. In the metformin group, there was a decrease in fat weight from 25.9 +/- 9.4 to 20.8 +/- 9.2 kg, p < 0.01, an increase in lean weight from 57.05 +/- 13.6 to 61.9 +/- 16.5 kg, p < 0.01, an increase in basal metabolism from 1735 +/- 413 to 1878 +/- 505 calories/day, p < 0.05 and an increase in body water, p < 0.05. There was no significant decrease in insulin resistance. In the placebo group, the blood glucose increased from 84.7 +/- 13 to 96.7 +/- 16 mg/dl, p < 0.05. There were no significant modifications in lipids.
conclusionsThe administration of metformin for 2 months improves the parameters of body composition and insulin dynamics in subjects with risk factors for type 2 DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.